TY - JOUR T1 - Genetic determinants of daytime napping and effects on cardiometabolic health JF - medRxiv DO - 10.1101/2020.06.12.20129858 SP - 2020.06.12.20129858 AU - Hassan S. Dashti AU - Iyas Daghlas AU - Jacqueline M. Lane AU - Yunru Huang AU - Miriam S. Udler AU - Heming Wang AU - Hanna M. Ollila AU - Samuel E. Jones AU - Jaegil Kim AU - Andrew R. Wood AU - 23andMe Research Team AU - Michael N. Weedon AU - Stella Aslibekyan AU - Marta Garaulet AU - Richa Saxena Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/16/2020.06.12.20129858.abstract N2 - Daytime napping is a common, heritable behavior, but its genetic basis and causal relationship with cardiometabolic health remains unclear. Here, we performed a genome-wide association study of self-reported daytime napping in the UK Biobank (n=452,633) and identified 123 loci of which 60 replicated in 23andMe research participants (n=541,333). Findings included missense variants in established drug targets (HCRTR1, HCRTR2), genes with roles in arousal (TRPC6, PNOC), and genes suggesting an obesity-hypersomnolence pathway (PNOC, PATJ). Signals were concordant with accelerometer-measured daytime inactivity duration and 33 signals colocalized with signals for other sleep phenotypes. Cluster analysis identified 3 clusters suggesting distinct nap-promoting mechanisms with heterogeneous associations with cardiometabolic outcomes. Mendelian randomization showed potential causal links between more frequent daytime napping and higher systolic blood pressure, diastolic blood pressure, and waist circumference.Competing Interest StatementYH, SA, and members of the 23andMe Research Team are employed by and hold stock or stock options in 23andMe, Inc.Funding StatementThis work is supported by grants NIH-F32DK102323, NIH-4T32HL007901, NIH-R01DK107859, NIH-R35HL135818, NIH-K23DK114551 (MSU), MGH Research Scholar Fund, Academy of Finland #309643 (HMO) and Medical Research Council grant: MR/M005070/1. This work has been supported in part by The Spanish Government of Investigation, Development and Innovation (SAF2017-84135-R) including FEDER co-funding; The Autonomous Community of the Region of Murcia through the Seneca Foundation (20795/PI/18) and NIDDK R01DK105072 granted to M. Garaulet. The MEGASTROKE project received funding from sources specified at http://www.megastroke.org/acknowledgments.html.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank study was approved by the National Health Service National Research Ethics Service (ref. 11/NW/0382). 23andMe analyses were reviewed and approved by Ethical & Independent Review Services, a private institutional review board (http://www.eandireview.com). Approval for analysis of Partners Biobank data was obtained by Partners IRB, protocol #2018P002276.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary GWAS statistics are publicly available at The Sleep Disorder Knowledge Portal webpage: www. http://sleepdisordergenetics.org/. http://sleepdisordergenetics.org/ ER -